Sponsors

Building a complete understanding of the vast complexities of biology, from single cells to tissues and beyond, requires multiomic approaches. At 10x Genomics, we provide single cell, spatial, and in situ technologies that fuel scientific discoveries and drive exponential progress. Uncover molecular insights, dissect cell-type differences, detect novel cell subtypes and biomarkers, define gene regulatory interactions, and decipher spatial gene expression patterns.

LevitasBio’s mission is to advance science and human health by providing researchers with a powerful, new method of cellular analysis. The last decade has seen tremendous advancement in analytical tools for genomics and proteomics such as next-generation sequencing, single cell genomics, and even phenotypic imaging down to single-cell resolution;but there has been no innovation in the sample preparation and cellular analysis market for decades – until now. We offer the first truly novel advancement in cellular analysis in 30 years. Our proprietary label-free Levitation Technology™ enables researchers to rescue and achieve higher quality and quantity of cells without introducing bias, high pressure, and modifications to gene expression profiles, ensuring the integrity of downstream data and analysis is maintained. The LeviCell® platform offers a revolutionary workflow in simplicity, speed, and reproducibility. Unlike traditional cell enrichment methods, it only requires 3 hands-on steps and has a 20-minute run from start to finish.

Standard BioTools Inc., the parent company of SomaLogic Inc. and previously known as Fluidigm, equips the life science industry with a unique suite of innovative and reliable multi-omic technologies that enable researchers to boldly explore life sciences challenges that advance human health. A pioneering technology, the SomaScan® Platform profiles 11,000 protein measurements, ideal for biomarker discovery. The SomaScan Assay provides researchers with the ability to measure thousands of proteins simultaneously, delivering unparalleled protein coverage and precision. This platform is vital for advancing biomarker discovery, accelerating the development of diagnostic tools and gaining deeper insights into complex biological systems.

Canopy Biosciences®, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our flagship CellScape™ Precise Spatial Multiplexing platform is a multiplex immunofluorescence imaging system for the whole-slide analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com.

Lunaphore Technologies S.A. – a Bio-Techne brand, is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.

Mission Bio specializes in the widespread adoption of single-cell DNA and multi-omic analysis. The Tapestri Platform is currently enabling advancements in cancer research, drug development, and cell and gene therapy, where understanding genetic heterogeneity at the single-cell level is crucial. This technology has the potential to lead to more personalized and effective treatment strategies. The level of precision and resolution provided is not easily achievable by combining bulk sequencing and other traditional methods.

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com.

Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data;robust quality control analysis;and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

Hologic Diagenode is a premier global provider of comprehensive solutions for epigenomics profiling services and sample preparation products tailored for next-generation sequencing, proteomics, and epigenetics research. We offer experimentally validated, user-friendly solutions and services for RNA, DNA, chromatin, and protein analysis, empowering researchers with the confidence and success needed to achieve exceptional results.

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories: Genomic Services, Clinical Trial Assays & Companion Diagnostics.

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

Leading provider of specialized precision medicine laboratory services with integrated platforms in immunology, histopathology, proteomics, genomics, and related specimen collection and logistics services. CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials, and operates globally with laboratories in Canada, USA, Belgium, Australia, and China.

Crown Bioscience, a JSR Life Sciences company, is a global CRO specializing in oncology drug discovery and development. It offers a range of preclinical and translational research services, including in vivo, in vitro, and ex vivo methodologies. The company supports drug development from discovery through clinical trials, with a diverse portfolio of oncology and immuno-oncology platforms and services for preclinical and translational research, complemented by multi-omics biomarker assays and bioanalytical services. With the acquisition of Indivumed Services, Crown Bioscience has expanded its biobank of human and liquid biospecimens linked to clinical data. It operates globally across the US, Europe, and APAC, with CAP and ISO-accredited labs.

Firalis Molecular Precision is a One-stop-shop CRO/CDMO equipped with high throughput Multi-Omics technologies dedicated to serve Biotech, Pharma, Academic Research and Health Organizations. Operating in 2 offices (Huningue, France in the heart of the BioValley and Cambridge, USA), Firalis Molecular Precision has a global team of 40+ efficient and reliable experts who have the appropriate knowledge and scientific expertise to understand your critical needs and provide robust trial. Inside its high qualified environment labs, Firalis Molecular Precision offers Multi-omics bioanalytical testing (genomics, transcriptomics, proteomics, lipidomics, metabolomics), biobanking infrastructure, assay development, data analysis and production facilities. Besides, as CDMO, Firalis Molecular Precision boasts a decade-long track record in the Assay-Development and Production sector, dedicated to overseeing the entire spectrum of processes crucial for obtaining CE marking and/or FDA approval for your products. Firalis’ Group certifications : ISO 9001:2015 (certification n° 2014/58992.7) : Quality management system; ISO 14001:2015 (certification n° 2022/100533.1) : Environmental management; ISO 13485:2016 (certification n° 2014/58993.6) : Development and production of immunoassays; ISO 20387 (certification n° 2016/71433.2) : Biobanking for research ; ISO 17025 :2017 (accreditation number n°8-3139) : testing activities. Firalis Molecular Precision is since end of August 2023 accredited by the CAP (College of American Pathologists).

Genseq provides advanced genomics solutions to the biopharma and clinical sectors worldwide. Operating from our ISO 15189 and CAP-accredited laboratory in Dublin, and equipped with state-of-the-art sequencing platforms, our highly experienced team consistently generates high quality multiomic data at scale to meet our customers’ diverse project goals. Genseq’s comprehensive range of laboratory services includes next-generation sequencing, single cell sequencing, microarrays, gene panel testing, non-invasive prenatal screening, bioinformatic analysis, biobanking and sample management. The data generated at Genseq has a broad range of applications ranging from diagnostics to biomarker identification and patient stratification for clinical trials. From sample receipt to data analysis, Genseq take care to maximise the potential of every sample, every time.

Inoviv delivers comprehensive, fully quantitative, and validated LC-MS biomarker solutions designed to accelerate clinical strategy. With decades of experience in discovery and targeted LC-MS proteomics workflows, our assays offer exceptional throughput, specificity, precision, and accuracy for regulatory submissions. We provide both custom-designed and pre-validated IP-MS and LC-MS assays for target identification, mechanism-of-action studies, and disease staging across various sample types, including biofluids, tissues, cell lysates, and more. Our bioinformatics expertise also enables biomarker selection support from exploratory studies, focusing on insightful discovery rather than data overload. Visit www.inoviv.com to schedule a meeting with our experts and discover how we can help accelerate your drug development goals.

MLM Medical Labs is a renowned central and specialty laboratory that operates globally, with a strong presence in Europe and North America. With a team of over 200 proficient and experienced professionals, MLM supports over 300 clinical studies concurrently. The company offers a vast array of services, including central lab testing, specialized and bespoke testing, histology, analysis of biomarkers, preclinical services, assay development, kit building, and long-term sample management and storage. MLM is headquartered in Mönchengladbach, Germany, near Düsseldorf, and has additional branches located in Memphis, TN, and Minneapolis, MN, in the USA. To learn more about MLM Medical Labs, please visit their website at, www.mlm-labs.com.

Sponsor biography coming soon

Rules-Based Medicine (RBM), an IQVIA business, is a leading multiplexed immunoassay testing laboratory offering internally developed multi-analyte profiles (MAPs) on the Luminex platform and ultrasensitive Simoa testing. RBM also performs the Olink Target 48 Cytokine panel with additional Olink testing coming soon. RBM provides reproducible and quantitative data for 300+ immunoassays, which provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments from its CLIA-certified biomarker testing laboratory in Austin, TX. RBM also has a novel whole blood immunophenotyping device (TruCulture®). TruCulture enables researchers to reproducibly ascertain information about immune responses to stress or stimulation, including responses to novel therapeutics.

Canopy Biosciences®, a Bruker company, empowers innovation by providing access to cutting-edge spatial biology and multi-omic tools so biomedical researchers can drive scientific discovery faster. Our flagship CellScape™ Precise Spatial Multiplexing platform is a multiplex immunofluorescence imaging system for the whole-slide analysis of complex tissues and mapping of cell populations with single-cell resolution. Supported by Canopy Spatial Services, we provide a unique collection of spatial and single-cell technologies that accelerate the understanding of cellular diversity and interaction. Learn more at CanopyBiosciences.com.

Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect MRD and recurrence at the earliest timepoints, enable selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development.

SomaLogic, a part of Standard BioTools, is catalyzing drug research and development and biomarker identification as a global leader in proteomics technology. With a single 55 microliter plasma or serum sample, SomaLogic can run 11,000 protein measurements, covering half the human proteome. For more than 20 years we’ve supported pharmaceutical companies, and academic and contract research organizations who rely on our protein detection and analysis technologies to fuel drug, disease, and treatment discoveries in such areas as oncology, diabetes, and cardiovascular, liver and metabolic diseases. Find out more at www.somalogic.com and follow @somalogic on LinkedIn.

At abcam, we believe the scientific community goes further, faster when we go there together. And to keep on making ground-breaking discoveries, we need to work together in new ways. That’s why we’re constantly innovating to help scientists drive their research forward by providing products and solutions that play an essential role in fundamental research, drug discovery, diagnostic and therapeutic applications. We started with a simple mission: to provide the best biological reagents to life scientists worldwide. Today, we help 750,000 researchers in over 130 countries deliver faster breakthroughs in areas like cancer, neurological disorders, infectious diseases, and metabolic disorders.

ARC Regulatory is an NI-based specialist regulatory and clinical research organisation, dedicated to supporting companies in the in vitro diagnostic and precision medicine sector. The company’s mission is to be the preferred partner for the global precision medicine and IVD industry, supporting the development of kinder treatments and expediting the highest quality clinical research for improved patient outcomes. In delivering this mission, ARC is proud to have supported more than 50 global biomarker-driven drug programmes with the world’s top targeted therapy R&D leaders.

Leading provider of specialized precision medicine laboratory services with integrated platforms in immunology, histopathology, proteomics, genomics, and related specimen collection and logistics services. CellCarta supports the entire drug development cycle, from discovery to late-stage clinical trials, and operates globally with laboratories in Canada, USA, Belgium, Australia, and China.

Discovery Life Sciences accelerates the discovery and development of new therapies and diagnostics by providing biopharma and diagnostic companies with the highest quality biospecimens, in vitro preclinical products, and cell & gene therapy starting materials coupled with specialty lab services that are grounded in science and offered at scale to support large scale clinical trials.

Olink offers an unmatched high-multiplex technique to identify actionable biomarkers, with a strong focus on the human plasma proteome. Using minimal sample volume we provide quantifiable results with high-throughput, exceptional sensitivity and specificity, with coverage across a broad dynamic range. Our mission is to accelerate proteomics together with the scientific community across multiple disease areas to enable new discoveries and better understand complex real-time human biology. We are committed to develop our offering and are continuously expanding our protein coverage for a growing number of biological processes and pathways. Olink is well-established in Europe (HQ Uppsala, Sweden) and the USA (HQ Boston, MA), with a rapidly developing presence across Asia. We also work with a growing number of core labs around the world offering analysis and support to an expanding global customer base. For more information visit www.olink.com

When Precision for Medicine’s name was chosen back in 2012, it signalled our commitment to a new movement shaping medical R&D, the movement to bring precision to the development of novel treatments. More than just a CRO, under one global roof, we’ve brought precision for medicine by integrating biomarker capabilities, worldwide CRO services, in-country regulatory expertise, specialty and central labs, technical manufacturing solutions and more. Precision is solving the intricate challenges our clients face when developing new therapeutics and together, we are propelling medicine forward.

Rules-Based Medicine (RBM), an IQVIA business, is a leading multiplexed immunoassay testing laboratory offering internally developed multi-analyte profiles (MAPs) on the Luminex platform and ultrasensitive Simoa testing. RBM also performs the Olink Target 48 Cytokine panel with additional Olink testing coming soon. RBM provides reproducible and quantitative data for 300+ immunoassays, which provides extensive coverage of numerous pathways and delivers accurate pharmacodynamic and safety assessments from its CLIA-certified biomarker testing laboratory in Austin, TX. RBM also has a novel whole blood immunophenotyping device (TruCulture®). TruCulture enables researchers to reproducibly ascertain information about immune responses to stress or stimulation, including responses to novel therapeutics.

Sapient is a biomarker discovery organization providing bespoke services for metabolomics, lipidomics, and proteomics data generation and analysis, enabling biopharma sponsors to go beyond the genome to accelerate precision drug development. Using state-of-the-art, high-throughput mass spectrometry technologies, Sapient enables nontargeted multi-omics measurements to capture thousands of dynamic biomarkers in human, preclinical, and cellular biosamples, across thousands of samples at a time. These technologies are leveraged within a larger discovery infrastructure that includes a comprehensive biocomputational framework for analysis of large-scale, multi-omics data;robust quality control analysis;and mapping of key biomarker-phenotype associations. Sapient can cross-validate discoveries using our proprietary in-house longitudinal Human Biology Database that includes data from over 100,000 human biosamples with paired phenotypic measures. Together our approaches enable rapid identification, validation, and translation of dynamic biomarkers of biological processes, disease mechanisms, and drug response across all drug development phases.

Seer develops innovative solutions that act as a gateway to the proteome. Our products are designed to accelerate the pace of proteomics by removing the technological barriers that stand between you and the proteomics you want to do. The Proteograph platform enables unbiased, deep, rapid, large-scale proteomics studies – the kind needed to advance our understanding of biology, health, and disease. It is now possible to accurately survey and analyze the full diversity of proteins across individuals, over time. Our goal is to empower the scientific community with tools for exceptional proteomics outcomes.

Sengenics, a functional proteomics company, is committed to advancing precision medicine by empowering researchers with biologically relevant and actionable immunoproteomic insights across a broad spectrum of diseases. At the heart of its mission, Sengenics offers advanced, high-throughput tools using proprietary technology to precisely detect autoantibody biomarkers and protein interactions for basic, translational, and clinical research. Its robust tools have been leveraged by top pharmaceutical companies and leading research institutions to enhance disease understanding and streamline the biomarker pipeline. Sengenics is headquartered in the U.S. and has a worldwide network of offices, distributors, and service providers.

Synexa is a global provider of biomarker and large molecule bioanalytical services, providing innovative solutions to support our customers achieve their clinical milestones. Synexa specialises in the development, validation, and delivery of a wide range of complex and custom-designed assays, performed across five laboratory locations in Cape Town, London, Berlin, Turku (Finland) and Rockville (Maryland USA). Our main areas of expertise are; biomarker identification and development, bioanalysis and soluble biomarkers (utilising MSD, ELISA, radioimmunoassay, fluorescence and luminescence-based technologies), cell biology (including flow cytometry and ELISpot) and genomic services to support clinical studies. With a focus on science and problem solving we pride ourselves on our ability to tackle complex problems which can be translated into robust and reliable assays to support clinical trial sample analysis.

Ultivue provides researchers with the clearest profile of cancer biology, enabling them to see more, see faster, and see in situ. Through Ultrasensitive InSituPlex® assays and advanced AI-driven STARVUE™ spatial image analysis pipeline, Ultivue empowers scientists developing precision cancer therapies to gain quantitative, high-confidence insights in just a fraction of the time.

Advancing you to your (pre)clinical milestones quickly, we are carefully engineered to support assay development and validation for your drug. Ardena's bioanalytical platform streamlines regulatory approval. Advanced. Proven. We accelerate your progress through (pre)clinical milestones.

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that transform science for better lives. With our versatile portfolio of next-generation proteomics solutions, including the TrueDiscovery®, TrueTarget®, and TrueSignature® research service platforms, our flagship software Spectronaut®, and the PQ500™ kit, we make the proteome actionable to empower research, drug development, and clinical decision-making. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Our unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins with industry-leading precision, depth, and throughput. Through our strategic partnership with Bruker (Nasdaq: BRKR), we make proteomics globally accessible. For more information, visit biognosys.com.

Cellecta Inc. is a trusted provider of genomic products and services for drug target and biomarker discovery. Since 2006, we have collaborated with the world’s leading pharma, biotech, government, and academic institutions. We apply our extensive expertise in viral vector production, functional screening, custom cell engineering and multiplex qRT-PCR to help researchers find the genes that matter.

Modernize and accelerate your research by expanding your capabilities with Diagnexia’s Research Pathology Services. Implementing Diagnexia’s digital workflow starts with high-quality, AI assisted whole-slide imaging and quality assurance. Your study’s slides are scanned by Diagnexia using our top of the line digital scanners at one of our scanning sites, available throughout the world to meet your needs. Those high-quality images can then be reviewed by Diagnexia’s sub-specialty pathology experts on Diagnexia’s Clinical Research platform, helping to expand your pathology capabilities, reducing pathology bottlenecks and ensuring high quality reads. Our Diagnexia Clinical Research platform is designed to accelerate case reviews, utilize AI tools for precision and build your library of comprehensive digital assets for additional insights for years to come. Partnering with Diagnexia ensures timely and comprehensive pathology analysis, with access to easy to recall whole slide images for current and future studies, saving time, energy and reducing the risk associated with shipping glass slides. Diagnexia’s unique level of expert pathologists can extend your capabilities assisting your team in working the pharmacology and identifying targets and biomarkers to help select the right candidates and targets.. Modernize your research by digitizing, accelerating and informing your clinical trials with Diagnexia.

ICON is the world’s leading clinical research organisation, powered by healthcare intelligence. From molecule to medicine, we advance clinical research providing outsourced development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employs approximately 41,150 employees in 113 locations in 53 countries. For further information, visit www.iconplc.com

Surfix is a Dutch diagnostics technology company founded in 2011 and headquartered in Wageningen. Surfix develops POCT solutions with lab precision, utilizing its photonic diagnostics platform that combines six state-of-the-art technologies. The platform is versatile: it can be used for immunoassays as well as for molecular diagnostics. Any protein or nucleic acid-based biomarker in a liquid biopsy can be detected, provided a suitable bioreceptor to capture this biomarker is available. The core of Surfix's diagnostics platform is a photonic biochip, which is integrated into a microfluidic cartridge, both optimized with Surfix's proprietary nanocoatings. The biosensor cartridge is used in combination with a dedicated desktop reader.

Almac Diagnostic Services support global pharma and biotech companies with their biomarker strategies from biomarker discovery through to companion diagnostic partnerships. Almac has clinical and research laboratories in Europe and the USA, alongside strategic partnerships in China, enabling us to support global studies. The services offered fall into three main categories:

• Genomic Services (Range of Platforms & Technologies, Sample Management, Data Sciences) • Clinical Trial Assays (Research Use Assays, Clinical Use Assays, Global Clinical Trial Testing) • Companion Diagnostics (CDx Development, CDx Manufacture, CDx Commercialisation)

https://www.almacgroup.com/diagnostics/

BioIVT enables smarter science and accelerates medical breakthroughs by delivering high-quality personalized biospecimen solutions and research services to life science and diagnostic industries. Recognized as an industry leader, we specialize in control and disease state samples including human and animal tissues or preparations, cell and gene therapy products, blood, and other biofluids, as well as ADME contract research services from standalone bioanalytical support through tiered in vitro studies with submission-ready reports to customized consulting. By combining our technical expertise, exceptional customer service, and unmatched access to biological specimens, BioIVT serves the research community as a trusted partner in ELEVATING SCIENCE®.

BioLizard is a leading multi-national bioinformatics, data analytics, AI and data management service and consulting company heading digital transformation in the life sciences industry. Headquartered in Ghent, Belgium, BioLizard is the trusted go-to partner for data strategy and execution with companies across the range from drug discovery to clinical research and diagnostics. BioLizard accommodates a uniquely qualified team of 50+ experts, ”The Lizards“, who bring together their expertise and abilities, covering data management, software engineering, bioinformatics, advanced data analytics, and AI. Their joint backgrounds in biology and computer sciences enables them to apply specialist understanding to each client’s data environment, to provide insights and tools that are aligned with the client’s goals and maximize R&D return on investment. Our tools cover literature search - Bio|Refelct, proprietary and public data integration across the full data and omics landscape - Bio|Mx, as well as microbiome specific analytical tools - ProBiome, all integrated in our Bio|Verse framework alongside your data and analytical pipelines.

Concept Life Sciences, a collaborative client-centred approach. We are a multi-disciplined Contract Research Organisation based in the UK providing market-leading scientific services globally. Over the past 25 years, Concept Life Sciences and its heritage companies have played a pivotal role in guiding numerous clients along their path to clinical success and many of these clients have evolved into enduring scientific collaborators. Within a decade, the collaborative efforts of experts from our heritage businesses — Peakdale Molecular, CXR Biosciences, and Aquila Biomedical — have propelled us beyond the cumulative impact of our individual components, fostering substantial growth and advancement. We are based across 4 research sites in the UK delivering discovery research, as well as GMP, GLP, and GCP-regulated work. Whether it is delivering whole programs of research, or bespoke studies, we deliever a a collaborative client-centred approach. Our services include discovery chemistry, specialist translational biology for immunology, oncology and neuroscience, biologics, biophysical assays services, ADMET & DMPK, bioanalysis, toxicology, histology, analytical services, including materials characterisation and physiochemical analysis, process research and development, and GMP manufacturing.

Firalis Molecular Precision is a One-stop-shop CRO/CDMO equipped with high throughput Multi-Omics technologies dedicated to serve Biotech, Pharma, Academic Research and Health Organizations. Operating in 2 offices (Huningue, France in the heart of the BioValley and Cambridge, USA), Firalis Molecular Precision has a global team of 30+ efficient and reliable experts who have the appropriate knowledge and scientific expertise to understand your critical needs and provide robust trial.

Inside its high qualified envrionment labs, Firalis Molecular Precision offers Multi-omics bioanalytical testing (genomics, transcriptomics, proteomics, lipidomics, metabolomics), biobanking infrastructure, assay development, data analysis and production facilities. Besides, as CDMO, Firalis Molecular Precision boasts a decade-long track record in the Assay-Development and Production sector, dedicated to overseeing the entire spectrum of processes crucial for obtaining CE marking and/or FDA approval for your products.

Firalis’ Group certifications :

- ISO 9001:2015 (certification n° 2014/58992.7) : Quality management system

- ISO 14001:2015 (certification n° 2022/100533.1) : Environnemental management

- ISO 13485:2016 (certification n° 2014/58993.6) : Development and production of immunoassays

- NFS96-900 (certification n° 2016/71433.2) : Biobanking for research (soon be replaced by the ISO 20387)

- ISO 17025 :2017 (accreditation number n°8-3139) : testing activities

Firalis Molecular Precision is since end of August 2023 accredited by the CAP (College of American Pathologists)

Hologic Diagenode is a leading provider in the field of epigenomics, with over 20 years of expertise. Our services can help you advance biomarker discovery and validation by combining the strengths of epigenomics and bioinformatics. This new dimension of epigenomics can offer novel insights that extend beyond genomics, aiding in early detection, patient screening, minimal residual disease (MRD) monitoring, and much more. We partner with you to create a customized, end-to-end service utilizing the best available technology to shorten timelines for translational research and biomarker validation before clinical trials.

Kymos is a GLP-certified and GCP-compliant multinational CRO inspected by the EMA and FDA. Our team of experts provides biomarker analysis, supporting you across all phases, from drug discovery to clinical sample analysis reaching multiple therapeutic areas. Equipped with state-of-the-art technologies and techniques such as Meso Scale Discovery (MSD®), Luminex®, qPCR, and LC-MS/MS, we offer a comprehensive catalog of biomarkers. This combination of expertise and technologies allows us to adapt and customize the biomarker determination according to each Clinical or Preclinical study’s specific needs. We are proficient in developing new methods from scratch, and depending on the study scope we can perform fit-to-purpose qualification or validation. Our team is experienced in pharmacodynamic studies to determine drug efficacy and safety (End-point determination), performing biomarker exploratory determinations, and screening of inflammatory markers as inclusion criteria for clinical studies.

Meso Scale Discovery (MSD) is a leader in high performance biological detection for preclinical and clinical research. MSD’s proprietary electrochemiluminescence (ECL) platform delivers single- and multiplex assays with exceptional sensitivity, dynamic range, and high-quality data. Our Services group provides expertise in method development for biomarker, PK, ADA and serology assays, including the use of several unique formats. Both bespoke and catalog assays can be run on your own MSD instrument or in our GCLP Bioanalytical Lab.

Mission Bio unlocks the ground truth of cancer through response, relapse, and remission with its Tapestri Platform, powered by single-cell multi-omics. As the first and only to analyze genotype and phenotype simultaneously in single cells, the Tapestri Platform can help unravel the inherent complexity of cancer. The technology discerns key biomarkers to stratify patients more precisely, signal treatment resistance as it begins, and predict relapse for better patient outcomes. Application areas include blood cancers, solid tumors, and genome editing validation. The Tapestri Platform is being utilized by customers at leading research centers, pharmaceutical, and diagnostics companies around the world to develop treatments and eventually cures for cancer. For example, researchers at Memorial Sloan Kettering Cancer Center (MSK), MD Anderson Cancer Center (MDACC), and the University of California at San Francisco (UCSF) have leveraged the Tapestri Platform to support their research for characterizing clonal dynamics in a variety of cancers, identifying minimal residual disease (MRD), and monitoring treatment response and therapy resistance. The company’s award-winning technology is also leveraged by LabCorp and Agios to enable more efficient clinical trials.

Volition is a leading epigenetics biomarker company, renowned for its proprietary liquid biopsy immunoassay approach to profiling cell-free circulating nucleosomes. Nu.Q® Discover, a fee for service model, offers access to assays that provide Non-Invasive, Real-Time, Quantitative insights, adding significant value in preclinical and clinical drug development programs across multiple therapeutic areas, including oncology and inflammatory diseases. Nu.Q® Discover, encompasses a range of assays targeting biomarkers associated with innate immune activation (NETosis) and epigenetic inhibitors (HDACi, LSDi, EZH2i, EEDi, SWI/SNF complex and more..). Nu.Q® assays effectively correlate with disease and tumor burden, making them ideal for use as surrogate endpoint markers of treatment response, minimal residual disease, and relapse monitoring. Our development pipeline includes assay development, a novel proteomics approach to epigenetic profiling of circulating nucleosomes using Mass Spec, and Toxicity Monitoring assays.

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon

Sponsor biography coming soon